|
US6710174B2
(en)
|
2001-09-13 |
2004-03-23 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of vascular endothelial growth factor receptor-1 expression
|
|
EP1353952B1
(en)
|
1994-11-14 |
2007-04-11 |
Ludwig Institute For Cancer Research |
Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
|
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
|
US7087411B2
(en)
*
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
US7070959B1
(en)
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
|
US7396664B2
(en)
|
1999-06-08 |
2008-07-08 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
US6833349B2
(en)
*
|
1999-06-08 |
2004-12-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating inflammatory skin diseases
|
|
US6734017B2
(en)
|
2001-09-28 |
2004-05-11 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of vascular endothelial growth factor receptor-2 expression
|
|
EP2301564A1
(en)
|
2002-05-04 |
2011-03-30 |
Acorda Therapeutics, Inc. |
Compositions and methods for promoting neuronal outgrowth
|
|
US7052691B2
(en)
*
|
2003-03-28 |
2006-05-30 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating diabetes by blocking VEGF-mediated activity
|
|
US7959914B2
(en)
|
2003-05-16 |
2011-06-14 |
Acorda Therapeutics, Inc. |
Methods of reducing extravasation of inflammatory cells
|
|
EP3514238B1
(en)
|
2003-05-16 |
2021-05-05 |
Acorda Therapeutics, Inc. |
Proteoglycan degrading mutants for treatment of cns
|
|
WO2004110359A2
(en)
*
|
2003-05-16 |
2004-12-23 |
Acorda Therapeutics, Inc. |
Fusion proteins for the treatment of cns
|
|
AU2004242586C1
(en)
*
|
2003-05-28 |
2011-02-24 |
Regeneron Pharmaceuticals, Inc. |
Method of treating corneal transplant rejection by using VEGF antagonists
|
|
US7186699B2
(en)
|
2003-06-03 |
2007-03-06 |
Cell Genesys, Inc. |
Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
|
|
EP1631317A2
(en)
*
|
2003-06-06 |
2006-03-08 |
Regeneron Pharmaceuticals, Inc. |
Use of vegf inhibitors for tumor regression
|
|
US7399612B2
(en)
|
2003-06-30 |
2008-07-15 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
AR046510A1
(es)
*
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
CA2534197A1
(en)
*
|
2003-08-06 |
2005-02-24 |
Thomas Jefferson University |
Use of a vegf antagonist in combination with radiation therapy
|
|
US8226941B2
(en)
|
2004-05-18 |
2012-07-24 |
Acorda Therapeutics, Inc. |
Methods of purifying chondroitinase and stable formulations thereof
|
|
KR100897379B1
(ko)
*
|
2004-06-08 |
2009-05-14 |
쳉두 캉홍 바이오테크놀로지스 코. 리미티드 |
혈관신생-저해 키메릭 단백질 및 그 사용
|
|
EP1753442A2
(en)
|
2004-06-10 |
2007-02-21 |
Regeneron Pharmaceuticals, Inc. |
Method of administering and using vegf inhibitors for the treatment of human cancer
|
|
MXPA06014689A
(es)
*
|
2004-06-18 |
2008-03-11 |
Regeneron Pharma |
Inhibidores del vegf para el tratamiento de efusion pleural maligna.
|
|
US7378095B2
(en)
|
2004-07-30 |
2008-05-27 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating type I diabetes by blocking VEGF-mediated activity
|
|
DK2229956T3
(da)
|
2004-09-13 |
2013-07-29 |
Genzyme Corp |
Multimere konstruktioner
|
|
FR2878749B1
(fr)
*
|
2004-12-03 |
2007-12-21 |
Aventis Pharma Sa |
Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
|
|
US7303748B2
(en)
|
2005-02-02 |
2007-12-04 |
Regeneron Pharmaceuticals, Inc. |
Method of treating eye injury with local administration of a VEGF inhibitor
|
|
CN102614134B
(zh)
|
2005-03-25 |
2016-09-07 |
瑞泽恩制药公司 |
Vegf拮抗剂制剂
|
|
JP5189985B2
(ja)
|
2005-09-26 |
2013-04-24 |
アコーダ セラピューティクス、インク． |
コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法
|
|
DK1962895T3
(da)
†
|
2005-12-16 |
2013-03-04 |
Regeneron Pharma |
TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST
|
|
FR2895258B1
(fr)
|
2005-12-22 |
2008-03-21 |
Aventis Pharma Sa |
Combinaison comprenant de la combretastatine et des agents anticancereux
|
|
CN100502945C
(zh)
*
|
2006-03-31 |
2009-06-24 |
成都康弘生物科技有限公司 |
Vegf受体融合蛋白在治疗眼睛疾病中的应用
|
|
US8216575B2
(en)
|
2006-03-31 |
2012-07-10 |
Chengdu Kanghong Biotechnologies Co., Ltd. |
Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
|
|
US7608261B2
(en)
|
2006-06-16 |
2009-10-27 |
Regeneron Pharmacuticals, Inc. |
VEGF antagonist formulations suitable for intravitreal administration
|
|
EA018260B1
(ru)
|
2006-09-29 |
2013-06-28 |
Онкомед Фармасьютикалз, Инк. |
Антитела к дельта-подобному лиганду 4 человека и их применение
|
|
US7722864B2
(en)
|
2006-10-10 |
2010-05-25 |
Acorda Therapeutics, Inc. |
Compositions and methods of using chondroitinase ABCI mutants
|
|
FR2918279B1
(fr)
*
|
2007-07-05 |
2010-10-22 |
Aventis Pharma Sa |
Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
|
|
CN101575379B
(zh)
*
|
2008-05-09 |
2012-05-30 |
上海抗体药物国家工程研究中心有限公司 |
可溶性vegfr双功能融合受体、其制备方法及用途
|
|
EP3785735A1
(en)
|
2008-11-03 |
2021-03-03 |
Molecular Partners AG |
Binding proteins inhibiting the vegf-a receptor interaction
|
|
CN101838329A
(zh)
*
|
2009-03-18 |
2010-09-22 |
嘉和生物药业有限公司 |
抗血管新生融合蛋白
|
|
ES2700450T3
(es)
|
2009-10-16 |
2019-02-15 |
Oncomed Pharm Inc |
Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
|
|
TWI510246B
(zh)
|
2010-04-30 |
2015-12-01 |
Molecular Partners Ag |
抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
|
|
PL2601214T3
(pl)
|
2010-08-06 |
2018-05-30 |
Genzyme Corporation |
Kompozycje antagonistyczne wobec VEGF oraz ich zastosowania
|
|
US20140080153A1
(en)
*
|
2011-01-07 |
2014-03-20 |
Chugai Seiyaku Kabushiki Kaisha |
Method for improving physical properties of antibody
|
|
KR20260004598A
(ko)
|
2011-01-13 |
2026-01-08 |
리제너론 파아마슈티컬스, 인크. |
혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
|
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
|
KR101397088B1
(ko)
|
2011-06-10 |
2014-05-19 |
강원대학교산학협력단 |
암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
|
|
JO3370B1
(ar)
*
|
2011-11-10 |
2019-03-13 |
Regeneron Pharma |
طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
|
|
BR112014013205A2
(pt)
|
2011-12-01 |
2020-10-27 |
Protevobio, Inc. |
proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
|
|
CN103304668B
(zh)
*
|
2012-03-12 |
2015-10-28 |
江苏健德生物药业有限公司 |
Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
|
|
HUE046134T2
(hu)
|
2012-05-07 |
2020-02-28 |
Allergan Inc |
Eljárás AMD kezelésére az anti-VEGF terápiára nem reagáló betegekben
|
|
WO2014006113A1
(en)
|
2012-07-03 |
2014-01-09 |
Sanofi |
Method of treating cancer by effective amounts of aflibercept
|
|
AR093445A1
(es)
|
2012-11-14 |
2015-06-10 |
Regeneron Pharma |
Metodos para tratar el cancer de ovario con antagonistas de dll4
|
|
PT2956476T
(pt)
|
2013-02-18 |
2020-02-21 |
Vegenics Pty Ltd |
Moléculas de ligação e usos destas
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
CN104193828B
(zh)
*
|
2013-09-12 |
2017-04-05 |
北京韩美药品有限公司 |
同时阻断her2和vegfr信号通路的重组融合蛋白
|
|
CA2927012A1
(en)
|
2013-11-05 |
2015-05-14 |
Allergan, Inc. |
Method of treating conditions of the eye with an anti-vegf darpin
|
|
RU2702748C2
(ru)
|
2014-05-12 |
2019-10-11 |
Формикон Аг |
Предварительно заполненный пластиковый шприц, содержащий антагонист vegf
|
|
KR102486321B1
(ko)
|
2014-07-18 |
2023-01-09 |
사노피 |
암을 앓고 있는 것으로 의심되는 환자를 아플리베르셉트로 치료한 결과를 예측하는 방법
|
|
JP2016036322A
(ja)
*
|
2014-08-11 |
2016-03-22 |
日本化薬株式会社 |
血管新生因子と結合するキメラタンパク質
|
|
PT3230316T
(pt)
|
2014-12-11 |
2022-02-24 |
Bayer Healthcare Llc |
Ratamento de degenerescência macular relacionada com a idade com uma pequena lesão de neovascularização coroideia ativa
|
|
GB201503453D0
(en)
|
2015-03-01 |
2015-04-15 |
Jain Arjun |
Endothelin-1"sponge"
|
|
TW202440904A
(zh)
|
2015-08-04 |
2024-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法（二）
|
|
WO2017046140A1
(en)
|
2015-09-18 |
2017-03-23 |
Bayer Pharma Aktiengesellschaft |
Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
|
|
WO2017065559A1
(ko)
|
2015-10-15 |
2017-04-20 |
(주)알테오젠 |
Igg fc 도메인을 가지는 융합 단백질의 생산방법
|
|
KR101936049B1
(ko)
*
|
2015-10-15 |
2019-01-08 |
(주)알테오젠 |
IgG Fc 도메인을 가지는 융합 단백질의 생산방법
|
|
WO2017087798A1
(en)
|
2015-11-18 |
2017-05-26 |
Formycon Ag |
Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
|
|
WO2018218013A2
(en)
|
2017-05-24 |
2018-11-29 |
Sio2 Medical Products, Inc. |
Sterilizable pharmaceutical package for ophthalmic formulations
|
|
CN108290004A
(zh)
|
2015-11-18 |
2018-07-17 |
福尔密孔股份公司 |
含有vegf拮抗剂的预填充塑料注射器
|
|
CA3005132A1
(en)
|
2015-11-18 |
2017-05-26 |
Sio2 Medical Products, Inc. |
Coated syringe for ophthalmic formulations containing a vegf antagonist
|
|
WO2017084616A1
(en)
*
|
2015-11-19 |
2017-05-26 |
Zhuhai Tairuishang Biopharm Ltd. |
Methods and compositions for binding vegf
|
|
PT3384049T
(pt)
|
2015-12-03 |
2023-08-18 |
Regeneron Pharma |
Método de associação de variantes genéticas com um resultado clínico em doentes que sofrem de degeneração macular relacionada à idade tratados com anti-vegf
|
|
AU2017213103B2
(en)
|
2016-01-26 |
2022-08-11 |
Formycon Ag |
Liquid formulation of a VEGF antagonist
|
|
WO2018070390A1
(ja)
|
2016-10-12 |
2018-04-19 |
第一三共株式会社 |
抗ｒｏｂｏ４抗体と他剤を含む組成物
|
|
CN109937034B
(zh)
|
2016-11-21 |
2022-09-16 |
济世-伊沃泰克生物制品有限公司 |
阿柏西普制剂及其用途
|
|
WO2018217995A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
|
WO2018215580A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Method for sterilizing prefilled plastic syringes containing a vegf antagonist
|
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
|
WO2019020777A1
(en)
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
|
DK3668985T3
(da)
|
2017-08-17 |
2021-09-20 |
Just Evotec Biologics Inc |
Fremgangsmåde til rensning af glycosyleret protein fra værtscellegalectiner og andre urenheder
|
|
CA3081094A1
(en)
|
2017-11-20 |
2019-05-23 |
Alison J. GILLESPIE |
Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
|
|
DK3717636T5
(da)
*
|
2017-11-27 |
2024-08-26 |
4D Molecular Therapeutics Inc |
Adeno-associeret-virus-variantcapsider og anvendelse til inhibering af angiogenese
|
|
EP4122486A1
(en)
|
2017-11-30 |
2023-01-25 |
Regeneron Pharmaceuticals, Inc. |
Use of a vegf antagonist to treat diabetic retinopathy
|
|
IL296138B2
(en)
*
|
2017-12-13 |
2024-11-01 |
Regeneron Pharma |
Devices and systems for chromatography column bed support management and related methods
|
|
KR102742284B1
(ko)
|
2017-12-22 |
2024-12-16 |
삼성바이오에피스 주식회사 |
Vegf 길항제를 포함하는 액상 조성물
|
|
FI3743091T3
(fi)
|
2018-01-26 |
2025-01-03 |
Univ California |
Menetelmät ja koostumukset verisuoniperäisten sairauksien hoitoon käyttämällä anti-vegf vaikuttavia aineita
|
|
MX2020009152A
(es)
|
2018-03-02 |
2020-11-09 |
Kodiak Sciences Inc |
Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
|
|
TW202016125A
(zh)
*
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
US11103552B2
(en)
|
2018-05-10 |
2021-08-31 |
Regeneron Pharmaceuticals, Inc. |
High concentration VEGF receptor fusion protein containing formulations
|
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
|
CN111378044B
(zh)
|
2018-12-28 |
2022-07-15 |
长春金赛药业有限责任公司 |
抗体融合蛋白、制备方法及其应用
|
|
WO2020229584A1
(en)
|
2019-05-16 |
2020-11-19 |
Formycon Ag |
Method for reducing methionine oxidation in recombinant proteins
|
|
MX2022002355A
(es)
|
2019-09-03 |
2022-04-06 |
Amgen Inc |
Dispositivo de inyeccion para suministro de farmacos y envase para el dispositivo de inyeccion.
|
|
US12233177B2
(en)
|
2019-09-16 |
2025-02-25 |
Amgen Inc. |
Method for external sterilization of drug delivery device
|
|
CA3157509A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
WO2021108255A1
(en)
|
2019-11-25 |
2021-06-03 |
The Regents Of The University Of California |
Long-acting vegf inhibitors for intraocular neovascularization
|
|
AU2020397053A1
(en)
|
2019-12-06 |
2022-06-23 |
Regeneron Pharmaceuticals, Inc. |
VEGF mini-traps and methods of use thereof
|
|
US11180540B2
(en)
|
2019-12-06 |
2021-11-23 |
Regeneron Pharmaceuticals, Inc. |
Anti-VEGF protein compositions and methods for producing the same
|
|
EP4110427A1
(en)
|
2020-02-24 |
2023-01-04 |
Amgen Inc. |
Containers and systems for use during external sterilization of drug delivery devices
|
|
JP2023525034A
(ja)
|
2020-05-08 |
2023-06-14 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
|
|
BR112023022439A2
(pt)
|
2021-04-26 |
2023-12-26 |
Celanese Eva Performance Polymers Llc |
Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
|
|
EP4145456A1
(en)
|
2021-09-06 |
2023-03-08 |
Bayer AG |
Prediction of a change related to a macular fluid
|
|
EP4438629A1
(en)
|
2021-11-24 |
2024-10-02 |
Suzhou Light Ferry Biomed. Co., Ltd |
Multispecific ligand binding molecule and application thereof
|
|
WO2024029876A1
(ko)
*
|
2022-08-02 |
2024-02-08 |
주식회사 파노로스바이오사이언스 |
변형된 융합 단백질 및 이의 용도
|
|
CN119584953A
(zh)
|
2022-09-16 |
2025-03-07 |
齐鲁制药有限公司 |
一种稳定的高浓度自缓冲药物组合物
|
|
AU2024322540A1
(en)
*
|
2023-08-04 |
2026-03-05 |
Panolos Bioscience, Inc. |
Conjugate of modified fusion protein and scfv, and use thereof
|
|
WO2025213011A1
(en)
|
2024-04-05 |
2025-10-09 |
Amgen Inc. |
Method of assessing stopper movement in a drug delivery device
|